Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Dr Reddy’s Laboratories ( (RDY) ) is now available.
On January 14, 2026, Dr. Reddy’s Laboratories announced it had launched in the U.S. market an over-the-counter Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, the first-to-market generic equivalent of Extra Strength Pataday Once Daily Relief, following approval by the U.S. Food and Drug Administration. The antihistamine eye drop, indicated for temporary relief of itchy eyes caused by allergens such as pollen, ragweed, grass, animal hair and dander, expands Dr. Reddy’s existing OTC eye-care portfolio, which already includes 0.2% and 0.1% olopatadine formulations; the move strengthens the company’s store-brand offering with U.S. retailers in a category where the Pataday brand generated about $69.9 million in U.S. sales in the 52 weeks to December 27, 2025, underscoring a meaningful new revenue opportunity and reinforcing its competitive positioning in the U.S. OTC market.
The most recent analyst rating on (RDY) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Dr Reddy’s Laboratories stock, see the RDY Stock Forecast page.
Spark’s Take on RDY Stock
According to Spark, TipRanks’ AI Analyst, RDY is a Outperform.
Dr Reddy’s Laboratories has a strong financial foundation and strategic growth initiatives, but faces challenges in the U.S. generics market and regulatory issues. The technical indicators suggest a bearish trend, and the valuation is reasonable but not compelling. The mixed sentiment from the earnings call reflects both opportunities and risks.
To see Spark’s full report on RDY stock, click here.
More about Dr Reddy’s Laboratories
Dr. Reddy’s Laboratories Ltd. is a global pharmaceutical company headquartered in Hyderabad, India, established in 1984. The company focuses on providing affordable and innovative medicines across a portfolio that includes APIs, generics, branded generics, biosimilars and over-the-counter (OTC) products, with key therapeutic areas spanning gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Its major markets include the U.S., India, Russia and CIS countries, China, Brazil and Europe, and it has a longstanding emphasis on sustainability and ESG initiatives.
Average Trading Volume: 1,129,337
Technical Sentiment Signal: Hold
Current Market Cap: $10.97B
For an in-depth examination of RDY stock, go to TipRanks’ Overview page.